Clinical Trial Update: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing secukinumab to etanercept in moderate to severe chronic plaque psoriasis completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Etanercept (etanercept)
• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2015-09-23